Immune checkpoint blockade (ICB) therapy has evolved as a revolutionized therapeutic
modality to eradicate tumor cells by releasing the brake of the antitumor immune response …

Melanoma is one of the seven most common cancers in the United States, and its incidence
is still increasing. Since 2011, developments in targeted therapies and immunotherapies …

Surgical resection, the mainstay for melanoma treatment, faces challenges due to high
tumor recurrence rates and complex postoperative wound healing. Chronic inflammation …

Pyroptosis is a programmed cell death characterized by the rupture of the plasma
membranes and release of cellular content leading to inflammatory reaction. Four cellular …

The incidence of melanoma, the most lethal form of skin cancer, has increased due to
ultraviolet exposure. The treatment of advanced melanoma, particularly metastatic cases …

Understanding the association of pyroptosis with tumor progression, prognosis and effect on
immunotherapeutic response in breast cancer (BC) is limited. This study analysed forty …

Molecularly targeted therapeutics have revolutionized the treatment of BRAFV600E‐driven
malignant melanoma, but the rapid development of resistance to BRAF kinase inhibitors …

Melanoma is a highly malignant skin cancer that is known for its resistance to treatments. In
recent years, there has been significant progress in the study of non-apoptotic cell death …

Drug resistance is a common challenge in clinical tumor treatment. A reduction in drug
sensitivity of tumor cells is often accompanied by an increase in autophagy levels, leading to …

Skin cutaneous melanoma (SKCM) is one of the most malignant skin cancers and remains a
health concern worldwide. Pyroptosis is a newly recognized form of programmed cell death …